LONDON – Erytech Pharma is to lead a €21 million (US$26.2 million) project to develop enzyme therapies that attack cancers by depleting amino acids in the tumor environment that are essential for tumor growth, and will also discover biomarkers to identify patients who are likely to respond to those treatments.